Congress moves to block expanded access to opioid-addiction medications

What it does

This bill nullifies a February 2024 HHS rule that expanded access to medications for opioid use disorder (primarily buprenorphine and methadone), except for the parts governing accreditation of treatment programs. The rule had loosened prescribing restrictions and expanded who could dispense these medications; voiding it restores prior, more restrictive rules and blocks patients from accessing these medications through newly permitted channels.

Why we flagged it

The bill's operative mechanism is to void a rule that expanded access to medications for opioid use disorder. Despite the clinical framing, the net effect is to restrict patient access to evidence-based treatment by reinstating prior prescribing limitations.

What the text implies

• Voiding the rule may disproportionately harm rural and underserved populations who relied on the expanded prescriber network to access buprenorphine and methadone.
• Reinstating prior restrictions could increase overdose deaths and emergency-department utilization among people with opioid use disorder who lose medication access.
• The carve-out for accreditation provisions suggests the bill targets prescribing/dispensing authority specifically, not program quality oversight.
• Patients already stabilized on medications obtained under the rule may face disruption or forced tapering if prescribers lose authority to continue treatment.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary people struggling with opioid use disorder lose access to evidence-based medications (buprenorphine, methadone) that the rule had made available through more providers and settings. Reinstating prior restrictions means fewer treatment options, longer wait times, and reduced access to life-saving medications, particularly in rural and underserved areas.

Who stands to gain

• Opioid treatment program operators (by reducing competition from newly authorized prescribers)
• Entities with financial interest in restricting medication access

Named in the bill

Department of Health and Human Services (HHS), 89 Fed. Reg. 7549, Title 42 Code of Federal Regulations Part 8 Subpart B, Mrs. Houchin (sponsor)

Where it stands

• Sep 30, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 30, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

6 lobbying clients named this bill on 8 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $1,343,462 in lobbying spend. A filing names 12 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 82% of bills with at least one filing.

Erin Houchin, the sponsor, reported $1,063,750 in PAC receipts in the 2026 cycle.

• Tobacco-free Kids Action Fund — $874,000 on 3 filings
• American Psychological Association Services Inc.(fka American Psychological Assn — $340,000 on 1 filing
• Association for Behavioral Health and Wellness — $69,462 on 1 filing
• American Association for the Treatment of Opioid Dependence — $20,000 on 1 filing
• Kelley Drye & Warren Llp Obo Tobacco-free Kids Action Fund — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.